Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms</title><author><name sortKey="Chen, Yuh Min" sort="Chen, Yuh Min" uniqKey="Chen Y" first="Yuh-Min" last="Chen">Yuh-Min Chen</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="AFF2">Division of Cancer Research, National Health Research Institute, Taipei, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Perng, Reury Perng" sort="Perng, Reury Perng" uniqKey="Perng R" first="Reury-Perng" last="Perng">Reury-Perng Perng</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chu, Hsi" sort="Chu, Hsi" uniqKey="Chu H" first="Hsi" last="Chu">Hsi Chu</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Whang Peng, Jacqueline" sort="Whang Peng, Jacqueline" uniqKey="Whang Peng J" first="Jacqueline" last="Whang-Peng">Jacqueline Whang-Peng</name><affiliation><nlm:aff id="AFF2">Division of Cancer Research, National Health Research Institute, Taipei, Taiwan</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15196733</idno><idno type="pmc">7133867</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133867</idno><idno type="RBID">PMC:7133867</idno><idno type="doi">10.1016/j.lungcan.2004.01.002</idno><date when="2004">2004</date><idno type="wicri:Area/Pmc/Corpus">001266</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001266</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms</title><author><name sortKey="Chen, Yuh Min" sort="Chen, Yuh Min" uniqKey="Chen Y" first="Yuh-Min" last="Chen">Yuh-Min Chen</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation><affiliation><nlm:aff id="AFF2">Division of Cancer Research, National Health Research Institute, Taipei, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Perng, Reury Perng" sort="Perng, Reury Perng" uniqKey="Perng R" first="Reury-Perng" last="Perng">Reury-Perng Perng</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Chu, Hsi" sort="Chu, Hsi" uniqKey="Chu H" first="Hsi" last="Chu">Hsi Chu</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name><affiliation><nlm:aff id="AFF1">Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</nlm:aff></affiliation></author><author><name sortKey="Whang Peng, Jacqueline" sort="Whang Peng, Jacqueline" uniqKey="Whang Peng J" first="Jacqueline" last="Whang-Peng">Jacqueline Whang-Peng</name><affiliation><nlm:aff id="AFF2">Division of Cancer Research, National Health Research Institute, Taipei, Taiwan</nlm:aff></affiliation></author></analytic><series><title level="j">Lung Cancer (Amsterdam, Netherlands)</title><idno type="ISSN">0169-5002</idno><idno type="eISSN">1872-8332</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Our aim was to describe the impact of severe acute respiratory syndrome (SARS) on the status and chemotherapy of non-small-cell lung cancer (NSCLC) patients who had entered clinical trials, and to review how to differentiate the signs and symptoms of SARS from lung cancer and its treatment-related toxicities. A prospective case series involving 79 NSCLC patients who were enrolled in clinical trials undergoing chemotherapy at Taipei Veterans General Hospital, between April 1 and July 15, 2003, was studied. Whether or not there existed a delay, omission, or refusal of scheduled chemotherapy, was recorded. Whether or not our patients had been suspected of or treated as having SARS, was recorded. The patients filled out questionnaires regarding lung cancer treatment and the risk of getting SARS from the hospital. Among these patients, five were placed in an isolation unit to rule out SARS infection during this period of time, and no patient was documented to have suffered from a SARS infection after examinations. Of 373 scheduled chemotherapy injections in 79 patients, a delay in treatment occurred only 10 times. Three patients refused further chemotherapy because of a fear of getting SARS if they visited the hospital. Fifty-eight patients responded to our questionnaires. Thirty-seven patients (63.8%) were afraid of visiting hospital during this SARS infection period. Twenty-one patients (36.2%) felt that a SARS infection was more severe and fatal than their lung cancer. In conclusion, SARS is a new disease entity that is highly contagious. Its clinical manifestations overlap with the signs and symptoms of lung cancer. Thus, a clear differentiation between the two conditions is needed, especially for those patients who are under active anti-cancer treatment.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Booth, C M" uniqKey="Booth C">C.M Booth</name></author><author><name sortKey="Matukas, L M" uniqKey="Matukas L">L.M Matukas</name></author><author><name sortKey="Tomlinson, G A" uniqKey="Tomlinson G">G.A Tomlinson</name></author><author><name sortKey="Rachlis, A R" uniqKey="Rachlis A">A.R Rachlis</name></author><author><name sortKey="Rose, D B" uniqKey="Rose D">D.B Rose</name></author><author><name sortKey="Dwosh, H A" uniqKey="Dwosh H">H.A Dwosh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, N" uniqKey="Lee N">N Lee</name></author><author><name sortKey="Hui, D" uniqKey="Hui D">D Hui</name></author><author><name sortKey="Wu, A" uniqKey="Wu A">A Wu</name></author><author><name sortKey="Chan, P" uniqKey="Chan P">P Chan</name></author><author><name sortKey="Cameron, P" uniqKey="Cameron P">P Cameron</name></author><author><name sortKey="Joynt, G M" uniqKey="Joynt G">G.M Joynt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spain, R C" uniqKey="Spain R">R.C Spain</name></author><author><name sortKey="Whittlesey, D" uniqKey="Whittlesey D">D Whittlesey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Y M" uniqKey="Chen Y">Y.M Chen</name></author><author><name sortKey="Perng, R P" uniqKey="Perng R">R.P Perng</name></author><author><name sortKey="Lin, W C" uniqKey="Lin W">W.C Lin</name></author><author><name sortKey="Wu, H W" uniqKey="Wu H">H.W Wu</name></author><author><name sortKey="Tsai, C M" uniqKey="Tsai C">C.M Tsai</name></author><author><name sortKey="Whang Peng, J" uniqKey="Whang Peng J">J Whang-Peng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Erasmus, J J" uniqKey="Erasmus J">J.J Erasmus</name></author><author><name sortKey="Mcadams, H P" uniqKey="Mcadams H">H.P McAdams</name></author><author><name sortKey="Rossi, S E" uniqKey="Rossi S">S.E Rossi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Erasmus, J J" uniqKey="Erasmus J">J.J Erasmus</name></author><author><name sortKey="Mcadams, H P" uniqKey="Mcadams H">H.P McAdams</name></author><author><name sortKey="Rossi, S E" uniqKey="Rossi S">S.E Rossi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, K T" uniqKey="Wong K">K.T Wong</name></author><author><name sortKey="Antonio, G E" uniqKey="Antonio G">G.E Antonio</name></author><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S Hui</name></author><author><name sortKey="Lee, N" uniqKey="Lee N">N Lee</name></author><author><name sortKey="Yuen, E H" uniqKey="Yuen E">E.H Yuen</name></author><author><name sortKey="Wu, A" uniqKey="Wu A">A Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Movsas, B" uniqKey="Movsas B">B Movsas</name></author><author><name sortKey="Raffin, T A" uniqKey="Raffin T">T.A Raffin</name></author><author><name sortKey="Epstein, A H" uniqKey="Epstein A">A.H Epstein</name></author><author><name sortKey="Link, C J" uniqKey="Link C">C.J Link</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Lung Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Lung Cancer</journal-id><journal-title-group><journal-title>Lung Cancer (Amsterdam, Netherlands)</journal-title></journal-title-group><issn pub-type="ppub">0169-5002</issn><issn pub-type="epub">1872-8332</issn><publisher><publisher-name>Elsevier Ireland Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15196733</article-id><article-id pub-id-type="pmc">7133867</article-id><article-id pub-id-type="publisher-id">S0169-5002(04)00008-X</article-id><article-id pub-id-type="doi">10.1016/j.lungcan.2004.01.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yuh-Min</given-names></name><email>ymchen@vghtpe.gov.tw</email><xref rid="AFF1" ref-type="aff">a</xref><xref rid="AFF2" ref-type="aff">b</xref><xref rid="COR1" ref-type="corresp">∗</xref></contrib><contrib contrib-type="author"><name><surname>Perng</surname><given-names>Reury-Perng</given-names></name><xref rid="AFF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Hsi</given-names></name><xref rid="AFF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Chun-Ming</given-names></name><xref rid="AFF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Whang-Peng</surname><given-names>Jacqueline</given-names></name><xref rid="AFF2" ref-type="aff">b</xref></contrib></contrib-group><aff id="AFF1"><label>a</label>Chest Department, Taipei Veterans General Hospital, and National Yang-Ming University, Shih-pai Road, Taipei 112, Taiwan</aff><aff id="AFF2"><label>b</label>Division of Cancer Research, National Health Research Institute, Taipei, Taiwan</aff><author-notes><corresp id="COR1"><label>*</label>Corresponding author. Tel.: +886-2-28757563; fax: +886-2-28763466. <email>ymchen@vghtpe.gov.tw</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>27</day><month>2</month><year>2004</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>7</month><year>2004</year></pub-date><pub-date pub-type="epub"><day>27</day><month>2</month><year>2004</year></pub-date><volume>45</volume><issue>1</issue><fpage>39</fpage><lpage>43</lpage><history><date date-type="received"><day>9</day><month>10</month><year>2003</year></date><date date-type="rev-recd"><day>29</day><month>12</month><year>2003</year></date><date date-type="accepted"><day>8</day><month>1</month><year>2004</year></date></history><permissions><copyright-statement>Copyright © 2004 Elsevier Ireland Ltd. All rights reserved.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Elsevier Ireland Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract><p>Our aim was to describe the impact of severe acute respiratory syndrome (SARS) on the status and chemotherapy of non-small-cell lung cancer (NSCLC) patients who had entered clinical trials, and to review how to differentiate the signs and symptoms of SARS from lung cancer and its treatment-related toxicities. A prospective case series involving 79 NSCLC patients who were enrolled in clinical trials undergoing chemotherapy at Taipei Veterans General Hospital, between April 1 and July 15, 2003, was studied. Whether or not there existed a delay, omission, or refusal of scheduled chemotherapy, was recorded. Whether or not our patients had been suspected of or treated as having SARS, was recorded. The patients filled out questionnaires regarding lung cancer treatment and the risk of getting SARS from the hospital. Among these patients, five were placed in an isolation unit to rule out SARS infection during this period of time, and no patient was documented to have suffered from a SARS infection after examinations. Of 373 scheduled chemotherapy injections in 79 patients, a delay in treatment occurred only 10 times. Three patients refused further chemotherapy because of a fear of getting SARS if they visited the hospital. Fifty-eight patients responded to our questionnaires. Thirty-seven patients (63.8%) were afraid of visiting hospital during this SARS infection period. Twenty-one patients (36.2%) felt that a SARS infection was more severe and fatal than their lung cancer. In conclusion, SARS is a new disease entity that is highly contagious. Its clinical manifestations overlap with the signs and symptoms of lung cancer. Thus, a clear differentiation between the two conditions is needed, especially for those patients who are under active anti-cancer treatment.</p></abstract><kwd-group><title>Keywords</title><kwd>Chemotherapy</kwd><kwd>Non-small-cell lung cancer (NSCLC)</kwd><kwd>Severe acute respiratory syndrome (SARS)</kwd></kwd-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>Severe acute respiratory syndrome (SARS) is a new infectious disease in humans, first recognized in late February 2003, in Hanoi, Vietnam <xref rid="BIB1" ref-type="bibr">[1]</xref>. Later, investigators found that SARS had first manifested in humans in Guangdong province in China, and subsequently spread worldwide <xref rid="BIB2" ref-type="bibr">[2]</xref>. A new coronavirus was identified as the causative agent of SARS. Taiwan was also affected by SARS from the end of February 2003, and the situation began worsening in April 2003 <xref rid="BIB3" ref-type="bibr">[3]</xref>. The majority of cases in the SARS outbreak in Taiwan were related to hospital exposure.</p><p>As defined by the WHO, a suspected case of SARS is an individual with fever (temperature >38 °C), cough, or dyspnea, and contact with an individual believed to have SARS, who has traveled to an area with recent local transmission of the disease, or who resides in an area with recent local transmission of SARS. A probable case is an individual meeting criteria for a suspected case along with radiographic features of pneumonia or respiratory distress syndrome, showing positive for SARS coronavirus in one or more assays, or having an unexplained respiratory illness resulting in death, with autopsy results demonstrating the pathology of respiratory distress syndrome without an identifiable cause <xref rid="BIB2" ref-type="bibr">[2]</xref>. As of August 7, 2003, probable SARS cases had been reported in 30 countries (32 areas), involving 8422 individuals, and causing 916 deaths <xref rid="BIB4" ref-type="bibr">[4]</xref>. Taiwan was the third most severely infected area, following China and Hong Kong.</p><p>Lung cancer patients frequently have pulmonary symptoms, such as cough and dyspnea. They easily suffer from fever, either due to infection, drug-induced causes, radiation, chemotherapy-induced febrile neutropenia, or tumor fever. Because of existing chest roentgenographic abnormalities and pulmonary symptoms, they are easily misdiagnosed as SARS patients, especially when fever occurs.</p><p>Taipei Veterans General Hospital is the leading center for chemotherapy clinical trials for lung cancer in Taiwan. It was also an important anti-SARS medical center during the SARS outbreak period in Taiwan. In this paper, we describe the experience of the impact of the SARS outbreak upon non-small-cell lung cancer (NSCLC) patients undergoing chemotherapy clinical trials in our hospital. As lung cancer patients have many clinical signs and symptoms similar to SARS patients, our experience may benefit others who may deal with lung cancer patients and a possible SARS outbreak in the near future.</p></sec><sec><label>2</label><title>Patients and methods</title><p>We prospectively followed our NSCLC patients who were enrolled in clinical trials undergoing chemotherapy at Taipei Veterans General Hospital, Taiwan, between April 1 and July 15, 2003. Whether or not there existed a delay, omission, or refusal of scheduled chemotherapy was recorded and the causes analyzed. Whether or not patients had been suspected of or treated as having SARS, or quarantined due to possible contact with SARS patients, was also recorded and the causes reviewed. The patients filled in questionnaires regarding the importance of lung cancer treatment and the risk of getting SARS during travel to or while staying in the hospital.</p></sec><sec><label>3</label><title>Results</title><p>Seventy-nine NSCLC patients were participating in our chemotherapy clinical trials between April 1 and July 15, 2003. Among them, five patients had been placed in our isolation unit to rule out SARS infection during this period, because they had exhibited clinical pictures similar to SARS infection or had a contact history with a SARS patient (<xref rid="TBL1" ref-type="table">Table 1</xref>). All five patients had a negative coronavirus study.<table-wrap position="float" id="TBL1"><label>Table 1</label><caption><p>Demographic data of five NSCLC patients who had been suspected of having SARS and were isolated<xref rid="TBLFN1" ref-type="table-fn">a</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Underlying condition</th><th>Presenting symptoms</th><th>Treatment</th><th>Outcome</th></tr></thead><tbody><tr><td>Docetaxel-induced interstitial pneumonitis</td><td>Progressive dyspnea, followed by mild fever after two cycles of treatment</td><td>Corticosteroid</td><td>Recovered</td></tr><tr><td>Lymphangitis carcinomatosis<xref rid="TBLFN2" ref-type="table-fn">b</xref></td><td>Progressive dyspnea and mild fever</td><td>Corticosteroid, antibiotics</td><td>Died 7 days later</td></tr><tr><td>Febrile neutropenia</td><td>Fever 7 days after chemotherapy</td><td>Antibiotics</td><td>Recovered</td></tr><tr><td>Post-obstructive pneumonitis</td><td>Productive cough, followed by fever</td><td>Antibiotics</td><td>Recovered</td></tr><tr><td>Hypoglycemia<xref rid="TBLFN2" ref-type="table-fn">b</xref></td><td>Loss of consciousness</td><td>Intravenous dextrose infusion</td><td>Recovered</td></tr></tbody></table><table-wrap-foot><fn id="TBLFN1"><label>a</label><p>All five patients had chest X-ray findings that were not easy to differentiate from SARS.</p></fn></table-wrap-foot><table-wrap-foot><fn id="TBLFN2"><label>b</label><p>These two patients had been staying in the same room with a probable SARS patient for 2 days and 1 day, respectively.</p></fn></table-wrap-foot></table-wrap></p><p>Of 373 scheduled chemotherapy injections for 79 patients, either in the outpatient clinic or under hospitalization, a delay in treatment occurred only 10 times. Three patients refused further chemotherapy because of a fear of getting SARS if they visited the hospital. Fifty-eight patients responded to our questionnaires. They all knew that a SARS outbreak had occurred in Taiwan, 63.8% of patients were afraid of visiting any hospital during this period, and 36.2% felt that the SARS infection was more severe and fatal than their lung cancer. The details are shown in <xref rid="TBL2" ref-type="table">Table 2</xref>.<table-wrap position="float" id="TBL2"><label>Table 2</label><caption><p>Results of questionnaires answered by 58 patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Item</th><th colspan="2">Patient number (%)<hr></hr></th></tr><tr><th></th><th>Yes</th><th>No</th></tr></thead><tbody><tr><td>Did you know about the SARS outbreak in Taiwan?</td><td>58 (100)</td><td align="char">0</td></tr><tr><td>Were you afraid to visit any hospital?</td><td>37 (63.8)</td><td align="char">21 (36.2)</td></tr><tr><td>Will you refuse to receive chemotherapy in our hospital if a SARS outbreak occurs here?</td><td>29 (50)</td><td align="char">29 (50)</td></tr><tr><td>Did you lose confidence in Taiwan’s hospitals?</td><td>16 (27.6)</td><td align="char">42 (72.4)</td></tr><tr><td>Did you feel that SARS was more severe and fatal than lung cancer?</td><td>21 (36.2)</td><td align="char">37 (63.8)</td></tr><tr><td>Did you worry your cancer condition would get worse due to the SARS outbreak?</td><td>46 (79.3)</td><td align="char">12 (20.7)</td></tr></tbody></table></table-wrap></p></sec><sec><label>4</label><title>Discussion</title><p>In Canada’s experience, SARS had spread to other patients and health care workers within the Toronto hospital prior to a significant awareness of SARS by the medical community. Other hospitals in Toronto were affected when patients were transferred between institutions <xref rid="BIB5" ref-type="bibr">[5]</xref>. The same situation occurred in Taiwan <xref rid="BIB3" ref-type="bibr">[3]</xref>. Thus, many patients were afraid to visit the hospital during the SARS infection period, due to a fear of being infected.</p><p>The earliest symptoms of SARS during the outbreak usually included fever or prodromal symptoms <xref rid="BIB5" ref-type="bibr">[5]</xref>, and the common clinical features at the time of admission were fever (99–100%), followed by nonproductive cough, myalgia, and dyspnea <xref rid="BIB5" ref-type="bibr">[5]</xref>, <xref rid="BIB6" ref-type="bibr">[6]</xref>. Unilateral and bilateral pulmonary infiltrates on chest radiography at admission were observed in 46% and 29% of SARS patients, respectively <xref rid="BIB5" ref-type="bibr">[5]</xref>. The differential diagnosis of pulmonary infiltrates is extensive in lung cancer patients with fever, including bacterial infection, opportunistic infection, pulmonary hemorrhage, lymphangitic carcinomatosis, pulmonary embolism, pulmonary edema, chemotherapy and/or radiotherapy-induced lung injury, and leukoagglutinin transfusion reactions <xref rid="BIB7" ref-type="bibr">[7]</xref>. It is difficult to use the chest roentgenogram alone for the differential diagnosis of lung cancer with or without SARS infection. Among the diagnoses that require differentiation, chemotherapy-induced febrile neutropenia, chemotherapy-induced interstitial pneumonitis, radiation penumonitis, and obstructive pneumonitis, were most commonly encountered (<xref rid="TBL3" ref-type="table">Table 3</xref>). The patient’s clinical history (treatment-related or SARS contact history), the temporal relationship between the different signs and symptoms, laboratory data, and image findings are all needed for the differential diagnosis (<xref rid="TBL3" ref-type="table">Table 3</xref>) <xref rid="BIB8" ref-type="bibr">[8]</xref>, <xref rid="BIB9" ref-type="bibr">[9]</xref>, <xref rid="BIB10" ref-type="bibr">[10]</xref>, <xref rid="BIB11" ref-type="bibr">[11]</xref>, <xref rid="BIB12" ref-type="bibr">[12]</xref>.<table-wrap position="float" id="TBL3"><label>Table 3</label><caption><p>Differential diagnosis of SARS infection and lung cancer patients with fever of different origins</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Disease</th><th>History (Hx)</th><th>Symptom/sign</th><th>Laboratory data</th><th>Image study</th></tr></thead><tbody><tr><td>SARS</td><td>SARS contact Hx (+)</td><td>Fever preceding cough and dyspnea</td><td>Lymphopenia, LDH ↑, coronavirus (+)</td><td>Uni- or bilateral infiltrates, usually multi-focal, mainly in the peripheral region and lower lobes</td></tr><tr><td>Febrile neutropenia</td><td>Chemotherapy Hx (+)</td><td>Mainly fever</td><td>Leukopenia, neutropenia</td><td>Usually no specific new lesion</td></tr><tr><td>Drug-induced interstitial pneumonitis</td><td>Chemotherapy Hx (+)</td><td>Progressive dyspnea preceding fever</td><td>No specific data</td><td>Uni- or bilateral progressive interstitial infiltration or consolidation</td></tr><tr><td>Radiation pneumonitis</td><td>1–3 months after radiotherapy</td><td>Dyspnea and/or dry cough preceding fever</td><td>No specific data</td><td>Hazy shadow similar to radiation ports</td></tr><tr><td>Obstructive pneumonitis</td><td>Cough and/or hemoptysis</td><td>Cough preceding fever</td><td>Leukocytosis</td><td>Mass with peripheral consolidation or collapse</td></tr></tbody></table></table-wrap></p><p>Despite the fact that 63.8% our patients said that they were afraid of visiting the hospital during the SARS infection period, the majority of the patients received chemotherapy on time because they also feared that their lung cancer condition would worsen if they delayed treatment. More importantly, none of our patients were infected with SARS during this SARS outbreak period, despite their frequent hospital visits.</p><p>In conclusion, when dealing with lung cancer patients receiving chemotherapy during a SARS epidemic, we suggest considering less myelosuppressive chemotherapy regimens. Consideration should be given to outpatient clinical treatment instead of hospitalization, changing the weekly treatment to treatment every 3 or 4 weeks, and changing from intravenous chemotherapy to an oral form of treatment, to avoid frequent hospital visits. Routine use of influenza vaccine is also recommended for these immunocompromised cancer patients as a way to help the patients and avoid the need to differentiate between a diagnosis of SARS and influenza infection. Patients should always bring a brief medical summary with the diagnosis, the treatment given, and the date of treatment; to avoid being mistaken as a SARS patient. Furthermore, in the future, other new, as yet undiscovered, respiratory pathogens that may cause problems similar to or worse than SARS, and the lessons learned from differentiation between SARS and lung cancer patients receiving chemotherapy could be applied to that situation.</p></sec></body><back><ref-list><title>References</title><ref id="BIB1"><label>1</label><mixed-citation publication-type="other">World health organization multicentre collaborative network for severe acute respiratory syndrome diagnosis. A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet 2003;361:1730–3.</mixed-citation></ref><ref id="BIB2"><label>2</label><mixed-citation publication-type="other">World Health Organization. Case definitions for surveillance of severe acute respiratory syndrome (SARS). Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/casedefinition/en">http://www.who.int/csr/sars/casedefinition/en</ext-link>. Accessed August 25, 2003.</mixed-citation></ref><ref id="BIB3"><label>3</label><mixed-citation publication-type="other">Anonymous. Severe acute respiratory syndrome, Taiwan, 2003. MMWR—Morbidity & Mortality Weekly Report 2003;52:461–6.</mixed-citation></ref><ref id="BIB4"><label>4</label><mixed-citation publication-type="other">World Health Organization. Summary table of SARS cases by country, 1 November 2002 to 7 August 2003. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/2003_08_15/en">http://www.who.int/csr/sars/country/2003_08_15/en</ext-link>. Accessed August 25, 2003.</mixed-citation></ref><ref id="BIB5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>C.M</given-names></name><name><surname>Matukas</surname><given-names>L.M</given-names></name><name><surname>Tomlinson</surname><given-names>G.A</given-names></name><name><surname>Rachlis</surname><given-names>A.R</given-names></name><name><surname>Rose</surname><given-names>D.B</given-names></name><name><surname>Dwosh</surname><given-names>H.A</given-names></name></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto area</article-title><source>JAMA</source><volume>289</volume><year>2003</year><fpage>2801</fpage><lpage>2809</lpage><pub-id pub-id-type="pmid">12734147</pub-id></element-citation></ref><ref id="BIB6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>P</given-names></name><name><surname>Joynt</surname><given-names>G.M</given-names></name></person-group><article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title><source>New Engl. J. Med.</source><volume>348</volume><year>2003</year><fpage>1986</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">12682352</pub-id></element-citation></ref><ref id="BIB7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spain</surname><given-names>R.C</given-names></name><name><surname>Whittlesey</surname><given-names>D</given-names></name></person-group><article-title>Respiratory emergencies in patients with cancer</article-title><source>Semin Oncol.</source><volume>16</volume><year>1989</year><fpage>471</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">2688108</pub-id></element-citation></ref><ref id="BIB8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.M</given-names></name><name><surname>Perng</surname><given-names>R.P</given-names></name><name><surname>Lin</surname><given-names>W.C</given-names></name><name><surname>Wu</surname><given-names>H.W</given-names></name><name><surname>Tsai</surname><given-names>C.M</given-names></name><name><surname>Whang-Peng</surname><given-names>J</given-names></name></person-group><article-title>Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy</article-title><source>Am. J. Clin. Oncol.</source><volume>25</volume><year>2002</year><fpage>509</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">12393994</pub-id></element-citation></ref><ref id="BIB9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erasmus</surname><given-names>J.J</given-names></name><name><surname>McAdams</surname><given-names>H.P</given-names></name><name><surname>Rossi</surname><given-names>S.E</given-names></name></person-group><article-title>Drug-induced lung injury</article-title><source>Semin Roentgeno</source><volume>37</volume><year>2002</year><fpage>72</fpage><lpage>81</lpage></element-citation></ref><ref id="BIB10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erasmus</surname><given-names>J.J</given-names></name><name><surname>McAdams</surname><given-names>H.P</given-names></name><name><surname>Rossi</surname><given-names>S.E</given-names></name></person-group><article-title>High-resolution CT of drug-induced lung disease</article-title><source>Radio Clin. North Am.</source><volume>40</volume><year>2002</year><fpage>61</fpage><lpage>72</lpage></element-citation></ref><ref id="BIB11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>K.T</given-names></name><name><surname>Antonio</surname><given-names>G.E</given-names></name><name><surname>Hui</surname><given-names>D.S</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Yuen</surname><given-names>E.H</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name></person-group><article-title>Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease</article-title><source>Radiology</source><volume>228</volume><year>2003</year><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">12738877</pub-id></element-citation></ref><ref id="BIB12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movsas</surname><given-names>B</given-names></name><name><surname>Raffin</surname><given-names>T.A</given-names></name><name><surname>Epstein</surname><given-names>A.H</given-names></name><name><surname>Link</surname><given-names>C.J</given-names><suffix>Jr.</suffix></name></person-group><article-title>Pulmonary radiation injury</article-title><source>Chest</source><volume>111</volume><year>1997</year><fpage>1061</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">9106589</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001266 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001266 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |